Comparative Pharmacology
Head-to-head clinical analysis: BENAZEPRIL HYDROCHLORIDE versus DEAPRIL ST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENAZEPRIL HYDROCHLORIDE versus DEAPRIL ST.
BENAZEPRIL HYDROCHLORIDE vs DEAPRIL-ST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benazepril is a prodrug that is hydrolyzed to benazeprilat, a competitive inhibitor of angiotensin-converting enzyme (ACE). This prevents conversion of angiotensin I to angiotensin II, resulting in decreased vasoconstriction, reduced aldosterone secretion, and lower blood pressure.
Angiotensin-converting enzyme (ACE) inhibitor. Inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Initial: 10 mg orally once daily. Titrate to 20-40 mg daily (as single dose or two divided doses). Maximum: 80 mg/day. Route: Oral.
Oral: 2.5 mg twice daily, titrated up to 5 mg twice daily as tolerated. Maximum dose: 10 mg daily.
None Documented
None Documented
Benazeprilat terminal elimination half-life is approximately 10-11 hours in patients with normal renal function; clinically, steady-state is reached in 2-3 days. Half-life is prolonged in renal impairment (up to 22 hours in moderate to severe impairment), necessitating dose adjustment.
8-10 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Primarily renal (80-90% of absorbed dose excreted in urine, with approximately 20-30% as benazeprilat and the rest as inactive metabolites); biliary/fecal elimination accounts for the remainder (10-20%).
Renal (90% as unchanged drug), biliary/fecal (10%)
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor